- Company targets Indian research peptide market with GMP-certified technology
- India's peptide therapeutics market projected to reach KRW 3 trillion by 2030
[by Lee, Young Sung] HLB PEP, a company specializing in peptide-based technologies, announced on August 5 the signing of an exclusive peptide material supply agreement with the Indian biotechnology firm Bioserve Biotechnologies. This agreement is expected to facilitate the global expansion of HLB PEP’s material exports.
Under the terms of the agreement, Bioserve will import high-quality peptide raw materials produced by 스피드 바카라 사이트 PEP and serve as the exclusive distributor for research use across India. 스피드 바카라 사이트 PEP emphasized the significance of this partnership, noting that it represents a meaningful step in expanding the global reach of 스피드 바카라 사이트 PEP’s peptide production technology, the only company in Korea to have obtained GMP certification.
Bioserve, a subsidiary of the Japanese regenerative medicine firm Reprocell, is widely recognized in India for its technological expertise, particularly in the fields of DNA synthesis and genetic analysis services. Its client base includes major Indian universities, public research institutes, and biotechnology companies.
Since its incorporation into the 스피드 바카라 사이트 Group in March, 스피드 바카라 사이트 PEP has actively pursued international market expansion. In May of this year, the company’s enuresis treatment raw material, ‘desmopressin,’ received approval as a finished pharmaceutical product. Furthermore, 스피드 바카라 사이트 PEP is expected to undergo a U.S. FDA inspection next year in preparation for the launch of its infertility treatment raw material, ‘Ganirelix,’ in the U.S. market.
"This agreement with Bioserve represents a strategic step toward expanding our sales in the highly promising Indian market,” said Shim Kyoung-jae, CEO of 스피드 바카라 사이트 PEP. “We expect strong synergy in the Indian biotechnology sector through collaboration with Bioserve, which possesses an extensive market network."
On the other hand, the Indian peptide therapeutics market is projected to reach USD 985 million (KRW 1.36 trillion) by 2023 and is expected to grow at a compound annual growth rate (CAGR) of 12.6%, reaching an estimated USD 2.26 billion by 2030.